Total Results: 433
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
As more patients receive hospice care at home, some of the powerful, addictive drugs they’re prescribed are ending up in the wrong hands.
The Food and Drug Administration approves a new Pfizer drug to treat a rare, fast-progressing form of leukemia. The agency also expands the use Lynparza, sold by AstraZeneca and Merck & Co, to treat recurrent ovarian cancer. In other pharmaceutical news, changes to 340B program are delayed and a biopharma executive encounters challenges when trying to fund his own project.
The $465 million settlement announced Thursday by the Department of Justice resolves claims that Mylan avoided paying rebates to the government by improperly classifying the EpiPen as a generic drug. Mylan and its auto-injector product have been at the center of the national debate over prescription drug costs.
Two Democratic lawmakers, Rep. Elijah Cummings of Maryland and Rep. Peter Welch of Vermont, are pressing Bayer, Biogen, EMD Serono, Novartis, Sanofi, Teva, and Roche Pharmaceuticals for an explanation of the pricing strategies and whether companies were increasing prices as part of a coordinated effort.
In related news, the nation’s largest pharmacy benefit manager is taking the controversial step of limiting the number and strength of first-time prescriptions for opioids. And let’s not forget about drugged drivers’ risk of overdose and new statistics that indicate the nation is drinking more.
Read recent commentaries about drug-cost issues.
News outlets report on stories related to pharmaceutical pricing.
Today’s early morning highlights from the major news organizations.
In other pharma industry news, the Food and Drug Administration issues new prescription advisories and recalls.
In a quick response to the announcement from Merck’s chief Kenneth Frazier, the president tweeted that the decision would give Frazier “more time to LOWER RIPOFF DRUG PRICES!”
The Senate quickly passed the bill that would allow dying patients access to experimental drugs after Sen. Ron Johnson (R-Wis.) had threatened to slow down consideration of a separate bill to renew the FDA’s fee-collection authority. In other drug industry news, the FDA is implementing new rules about hiring foreign scientists, industry tightens controls to keep out counterfeit drugs, cancer trials are low on patients and costs of old drugs rising quickly for Medicaid.
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
A selection of opinions on health care from around the country.
Each week, KHN compiles a selection of recently released health policy studies and briefs.
Media outlets report on news from Arizona, Connecticut, Florida, Washignton, Texas, Missouri, New York, Delaware, Ohio, Wisconsin and Maryland.
The company is the latest to slash their forecast due to generic drugs.
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
Martin Shkreli was found guilty of three counts of fraud and faces a possible prison sentence. But how has his case affected the pharmaceutical industry?
Last year, a fierce battle emerged over Sarepta’s new muscular dystrophy drug, in which FDA official Janet Woodcock approved the treatment — overruling the recommendations of a review team and an advisory committee. Newly released emails show what happened next.